ClinicalTrials.gg
CompletedNCT02555176Updated May 20, 2025

Low-Carbohydrate Normocaloric Diet in Patients With Head and Neck Carcinoma (HNC)

An interventional study of Dietary intervention in Head and Neck Carcinoma, sponsored by Sidney Kimmel Cancer Center at Thomas Jefferson University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-20.

Sponsored by Sidney Kimmel Cancer Center at Thomas Jefferson University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
7
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This pilot clinical trial studies the effects of a low carbohydrate diet on tumor metabolism in patients with head and neck cancer. A low carbohydrate diet may reduce the metabolic activity of cancer cells and of surrounding supportive tissues. Studying samples of tissue and blood from patients with head and neck cancer in the laboratory before and after a low carbohydrate diet may help determine any changes in tumor metabolism.

Read the detailed description

PRIMARY OBJECTIVES:

I. Assess the impact of a low-carbohydrate normocaloric diet on transporter of the outer mitochondrial membrane subunit 20 (TOMM20) expression by immunohistochemistry (IHC) in carcinoma cells and the impact of a low-carbohydrate normocaloric diet on monocarboxylate transporter 4 (MCT4) expression in fibroblasts.

SECONDARY OBJECTIVES:

I. Assess the feasibility of a low-carbohydrate normocaloric diet treatment in head and neck carcinoma (HNC) patients.

II. Assess the effect of a low-carbohydrate normocaloric diet on the serum levels of insulin, and insulin growth factor (IGF)-1 and -2.

III. Assess the potential impact of a low-carbohydrate normocaloric diet on the following: disease-free survival, distant metastases-free survival, overall survival.

IV. To evaluate the utility of cancer-derived exosomes to serve as prognostic biomarkers for real-time monitoring of therapeutic efficacy and identifying early recurrence using longitudinal samples from cancer patients undergoing treatment.

OUTLINE:

Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).

After completion of study, patients are followed up at 1 month, 3 months, and then every 3 months for 24 months.

02

Conditions studied

  • Head and Neck Carcinoma
03

In context

Lead sponsor

Sidney Kimmel Cancer Center at Thomas Jefferson University is the lead sponsor of 120 studies on the registry; none are open to participants now.

Of its 23 completed or terminated interventional studies of FDA-regulated products, 7 (30%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with a diagnosis of head and neck cancer proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH are eligible to participate.
  2. Subjects must be ≥ 18 and ≤ 70 years of age.
  3. > 70
  4. Expected survival > 6 months.
  5. Adequate organ functions (hematological, hepatic, renal function).
  6. > 1.5 x 109/L, count > 100 x 109/L, > 9 g/L, total \< 1.25 x the institutional [ULN], albumin > 2.5 g/dL, \< 45 IU/dL, alanine aminotransferase \< 40 IU/dL, alkaline phosphatase ≤ 190 IU/dL and serum creatinine \< 1.3 mg/dL and > 50 mL/min.
  7. Serum potassium and magnesium, and corrected serum calcium within the institution's normal reference range.
  8. Ability to provide written obtained prior to participation in the study.
  9. Women of (WOCBP) must be willing to use an adequate method of to avoid pregnancy throughout the study in such a manner that the risk of pregnancy is minimized.
  10. Patients' availability to check their weight twice per week, during the study duration.

Exclusion criteria

Exclusion Criteria:

  1. Diabetic patients are eligible but will be excluded if they are taking metformin, insulin or sulfonilureas.
  2. Patients with plasma greater than 40 IU/dL.
  3. Patients with plasma aspartate aminotransferase greater than 45 IU/dL.
  4. Patients with plasma creatinine level greater than 1.3 mg/dL.
  5. Patients with plasma alkaline phosphatase greater than 190 IU/dL.
  6. Patients with plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis.
  7. Patients with history of congestive heart failure.
  8. Patients with myocardial ischemia or peripheral muscle ischemia.
  9. Patients with sepsis or severe infection.
  10. Patients with history of lung disease currently requiring any pharmacologic or supplemental oxygen treatment.
  11. Patients scheduled for definitive HNC cancer surgical resection less than 10 days from enrollment or greater than five weeks from enrollment.
  12. Patients with history of hepatic dysfunction or hepatic disease.
  13. Patients with a history of excessive alcohol intake which is defined in accordance with CDC definitions as more than 1 drink per day for women and more than 2 drinks per day for men. This definition is referring to the amount consumed on any single day and is not intended as an average over several days. A standard drink is equal to 13.7 grams (0.6 ounces) of pure alcohol. Generally, this amount of pure alcohol is found in 12-ounces of beer, 8-ounces of malt liquor, 5-ounces of wine, 1.5-ounces or a "shot" of 80-proof distilled spirits or liquor (e.g., gin, rum, vodka, or whiskey).
  14. Patients with a lower (BMI\<18) will be excluded.
  15. Patients with history of known defects in fat metabolism (ie pyruvate carboxylase deficiency, prophyria, fatty acid oxidation defects, primary carnitine deficiencies, organic acidurias, hypoglicemia) will be excluded.
  16. Pregnancy, lactation or inability to use medically acceptable if of .
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
7 participants (actual)

Study arms

  • Experimental
    Low Carbohydrate Diet

    Patients follow a normocaloric, low-carbohydrate diet for 10-28 days (from the time of cancer diagnosis to definitive surgical treatment).

    Dietary Supplement: Dietary intervention

Interventions

  • Dietary supplementDietary intervention

    Follow a low-carbohydrate diet

06

What researchers measure

Primary outcomes

  1. Change in TOMM20 expression by IHC

    IHC status will be classified as positive or negative pre-and post-treatment. Change in IHC status will be evaluated using McNemar's test for paired dichotomous data.

    Time frame: Baseline to up to 28 days (day of surgery)

  2. Change in MCT4 expression in fibroblasts

    IHC status will be classified as positive or negative pre-and post-treatment. Change in IHC status will be evaluated using McNemar's test for paired dichotomous data.

    Time frame: Baseline to up to 28 days (day of surgery)

  3. Incidence of adverse events, evaluated using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events version 4.0

    Time frame: Up to 24 months after surgery

Secondary outcomes

  1. Feasibility of a low-carbohydrate normocaloric diet treatment in HNC patients

    Analysis will be descriptive

    Time frame: Up to 28 days

  2. Change in serum levels of insulin

    Time frame: Baseline to up to 24 months

  3. Change in serum levels of IGF-1

    Time frame: Baseline to up to 24 months

  4. Change in serum levels of IGF-2

    Time frame: Baseline to up to 24 months

  5. Disease-free survival

    Estimated using the Kaplan-Meier method.

    Time frame: Up to 24 months after surgery

  6. Distant metastases-free survival

    Estimated using the Kaplan-Meier method.

    Time frame: Up to 24 months after surgery

  7. Overall survival

    Estimated using the Kaplan-Meier method.

    Time frame: Up to 24 months after surgery

07

Study locations

1 site
  • Thomas Jefferson University
    Philadelphia, Pennsylvania 19107, United States
08

References and documents

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02555176
Responsible party
Sponsor
First posted
Sep 21, 2015
Start date
Dec 14, 2016
Primary completion
Jan 2017
Completion
Oct 2018
Last update
May 20, 2025

Study contacts

Joseph Curry, MD
principal investigator · Thomas Jefferson University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion